Core Insights - Lymphoma is the 10th most common cancer globally and has the fastest-growing incidence rate among malignant tumors, with approximately 100,000 new cases annually in China, over 50% of which are in individuals aged 60 and above [1][2] - The Chinese government has made significant progress in lymphoma diagnosis, treatment guidelines, and quality control measures, including the establishment of pilot programs for standardized treatment [1][4] - The approval of innovative drugs, such as tanzimab and lenalidomide for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL), marks a significant advancement in lymphoma treatment options [2][3] Industry Developments - The National Medical Products Administration conditionally approved tanzimab for adult patients with relapsed or refractory follicular lymphoma in November 2022, and its combination therapy for DLBCL was approved in May 2023 [2][3] - Clinical studies show promising results for tanzimab, with an overall response rate (ORR) of 57.5% and a complete response (CR) rate of 41.3% in global studies, while Chinese patients showed an ORR of 73.1% [3] - The 2023 "Healthy China Action - Cancer Prevention and Control Implementation Plan" aims to enhance cancer prevention and treatment capabilities, targeting a 5-year survival rate of 46.6% by 2030 [4][5]

Core Insights - The current focus of lymphoma discipline construction in China includes advancements in diagnostic and treatment technologies, as well as multi-disciplinary collaboration models [1] - The upcoming live session will feature Jin Jie, a prominent figure in the field, discussing the balance between technological empowerment and humanistic care in the medical environment [1] Group 1: Industry Developments - The level of lymphoma diagnosis and treatment in China has been continuously improving in recent years [1] - Notable breakthroughs in the industry include innovations in diagnostic and treatment technologies and collaborative models across multiple disciplines [1] Group 2: Event Details - A live discussion will take place on August 19 from 14:00 to 15:00, featuring Jin Jie, who is a distinguished professor and leader in the field of hematology [1][3] - The session aims to explore how to achieve a balance between technology and humanistic care in the current healthcare environment [1] Group 3: Access Information - Viewers can watch the live session by downloading the People's Good Doctor App and navigating to the "Famous Doctor Live" section [5] - Alternatively, viewers can follow the People's Health public WeChat account to access the app for the live broadcast [5]